Puma Biotechnology SEC filings document an oncology biopharmaceutical business whose reported net product revenue comes from sales of NERLYNX®, its commercial oral neratinib product for HER2-positive breast cancer. Form 8-K reports furnish quarterly and annual operating results, financial-condition updates and exhibit press releases, including disclosures on revenue categories, cost of sales and guidance.
Proxy materials cover board matters, executive compensation and equity-award information, while material-event filings record governance actions such as amendments to the company’s bylaws. The filing record also provides formal context for common stock listed on the Nasdaq Global Select Market and development disclosures related to alisertib and Puma’s oncology programs.
A company insider filed a Form 144 notice to sell 18,012 shares of common stock through Fidelity Brokerage Services on or about 01/07/2026, with an indicated aggregate market value of $105,892.55. The notice cites that there were 50,391,107 shares of this class outstanding, giving context for the size of the planned sale.
The shares to be sold come from restricted stock vesting on 01/02/2026, received from the issuer as compensation, with the same date shown as the payment date. In the past three months, the insider, identified as Alan Auerbach, previously sold 16,938 common shares on 01/06/2026 for $98,978.90.
Douglas Hunt filed a notice under Rule 144 to sell 5,014 shares of common stock through Fidelity Brokerage Services LLC on or about 01/07/2026 on the NASDAQ market. These 5,014 shares were acquired on 01/02/2026 via restricted stock vesting from the issuer as compensation. The filing notes that 50,391,107 shares of the issuer’s common stock were outstanding. During the prior three months, Hunt sold 3,973 common shares on 01/06/2026 for gross proceeds of 24,216.62.
A shareholder filed a Rule 144 notice to sell 6,405 shares of common stock of the issuer through Fidelity Brokerage Services LLC on 01/07/2026, with an aggregate market value of $37,655.00. The filing notes that there are 50,391,107 shares of this common stock outstanding and that the shares to be sold were acquired on 01/02/2026 via restricted stock vesting as compensation from the issuer. Over the prior three months, the same seller, Maximo Nougues, sold 4,540 common shares for gross proceeds of $26,529.94. The signer represents that they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
An affiliate of the issuer has filed a notice of proposed sale under Rule 144 covering up to 3,973 shares of common stock. These shares are planned to be sold through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 01/06/2026 and an indicated aggregate market value of 23,216.62. The filing notes that 50,391,107 shares of this class were outstanding at the time referenced.
The 3,973 shares were acquired on 01/02/2026 directly from the issuer through restricted stock vesting as compensation. The section for securities sold during the past three months does not list any prior sales, and the signer represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Puma Biotechnology (PBYI) reported an insider transaction by a director. On 11/11/2025, the reporting person sold 20,000 shares of common stock at a weighted average price of $4.8614, with trades executed between $4.82 and $4.97. Following the sale, the insider directly owns 54,000 shares. The filing notes the seller will provide full trade‑level details upon request.
Puma Biotechnology (PBYI) reported Q3 2025 results. Total revenue was $54.5 million, with product revenue of $51.9 million and royalty revenue of $2.6 million. Net income was $8.8 million, or $0.17 per diluted share. Operating costs and expenses were $44.9 million, yielding income from operations of $9.6 million.
For the nine months ended September 30, 2025, revenue was $152.9 million and net income was $17.7 million. Operating cash flow totaled $27.4 million. Cash, cash equivalents and marketable securities were $94.4 million as of September 30, 2025. Long-term debt, net, was $0 at quarter-end, and the current portion of long-term debt was $33.7 million.
Stockholders’ equity rose to $115.3 million from $92.1 million at year-end. Shares outstanding were 50,391,107 as of November 3, 2025. The company continues to commercialize NERLYNX and to develop alisertib under its license from Takeda.
Puma Biotechnology (PBYI) reported that it issued a press release announcing financial results for the third quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 to this report.
The company states the information under Item 2.02 is being furnished, not filed under the Exchange Act and will not be incorporated by reference into other filings. Additional exhibits include Exhibit 104 (Cover Page Interactive Data File in inline XBRL).